Statin induced rhabdomyolysis with non oliguric renal failure

A rare presentation

Hashir Kareem, Devavrata Sahu, Mugula Sudhakar Rao, Tom Devasia

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Statins are safe, well tolerated, efficient and time tested drugs for the management of hypercholesterolemia, and thus play a cardinal role in the management of patients with heart disease. Although safe in clinical practice, they are associated with adverse effects, clinically the most important and most severe being muscle related complications/myotoxicity. Rhabdomyolysis, though rare, is the most severe form of myotoxicity. The US Food and Drug Administration (USFDA) adverse event reporting system reports rate of statin induced rhabdomyolysis at 0.3-13.5 cases per 1,000,000 patients. We present a case of a 74-year-old male who presented with an acute coronary syndrome and was initiated on atorvastatin. However, patient developed atorvastatin induced rhabdomyolysis, with non oliguric renal failure, which subsequently improved on cessation of medication.

Original languageEnglish
Pages (from-to)FD01-FD02
JournalJournal of Clinical and Diagnostic Research
Volume11
Issue number3
DOIs
Publication statusPublished - 01-03-2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Rhabdomyolysis
Renal Insufficiency
Muscle
Acute Coronary Syndrome
Hypercholesterolemia
Drug-Related Side Effects and Adverse Reactions
Heart Diseases
Pharmaceutical Preparations
Food
Muscles
Atorvastatin Calcium

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

Kareem, Hashir ; Sahu, Devavrata ; Rao, Mugula Sudhakar ; Devasia, Tom. / Statin induced rhabdomyolysis with non oliguric renal failure : A rare presentation. In: Journal of Clinical and Diagnostic Research. 2017 ; Vol. 11, No. 3. pp. FD01-FD02.
@article{8d562bfc902d4ac98a482cb16ecd4ba8,
title = "Statin induced rhabdomyolysis with non oliguric renal failure: A rare presentation",
abstract = "Statins are safe, well tolerated, efficient and time tested drugs for the management of hypercholesterolemia, and thus play a cardinal role in the management of patients with heart disease. Although safe in clinical practice, they are associated with adverse effects, clinically the most important and most severe being muscle related complications/myotoxicity. Rhabdomyolysis, though rare, is the most severe form of myotoxicity. The US Food and Drug Administration (USFDA) adverse event reporting system reports rate of statin induced rhabdomyolysis at 0.3-13.5 cases per 1,000,000 patients. We present a case of a 74-year-old male who presented with an acute coronary syndrome and was initiated on atorvastatin. However, patient developed atorvastatin induced rhabdomyolysis, with non oliguric renal failure, which subsequently improved on cessation of medication.",
author = "Hashir Kareem and Devavrata Sahu and Rao, {Mugula Sudhakar} and Tom Devasia",
year = "2017",
month = "3",
day = "1",
doi = "10.7860/JCDR/2017/24491.9359",
language = "English",
volume = "11",
pages = "FD01--FD02",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "3",

}

Statin induced rhabdomyolysis with non oliguric renal failure : A rare presentation. / Kareem, Hashir; Sahu, Devavrata; Rao, Mugula Sudhakar; Devasia, Tom.

In: Journal of Clinical and Diagnostic Research, Vol. 11, No. 3, 01.03.2017, p. FD01-FD02.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statin induced rhabdomyolysis with non oliguric renal failure

T2 - A rare presentation

AU - Kareem, Hashir

AU - Sahu, Devavrata

AU - Rao, Mugula Sudhakar

AU - Devasia, Tom

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Statins are safe, well tolerated, efficient and time tested drugs for the management of hypercholesterolemia, and thus play a cardinal role in the management of patients with heart disease. Although safe in clinical practice, they are associated with adverse effects, clinically the most important and most severe being muscle related complications/myotoxicity. Rhabdomyolysis, though rare, is the most severe form of myotoxicity. The US Food and Drug Administration (USFDA) adverse event reporting system reports rate of statin induced rhabdomyolysis at 0.3-13.5 cases per 1,000,000 patients. We present a case of a 74-year-old male who presented with an acute coronary syndrome and was initiated on atorvastatin. However, patient developed atorvastatin induced rhabdomyolysis, with non oliguric renal failure, which subsequently improved on cessation of medication.

AB - Statins are safe, well tolerated, efficient and time tested drugs for the management of hypercholesterolemia, and thus play a cardinal role in the management of patients with heart disease. Although safe in clinical practice, they are associated with adverse effects, clinically the most important and most severe being muscle related complications/myotoxicity. Rhabdomyolysis, though rare, is the most severe form of myotoxicity. The US Food and Drug Administration (USFDA) adverse event reporting system reports rate of statin induced rhabdomyolysis at 0.3-13.5 cases per 1,000,000 patients. We present a case of a 74-year-old male who presented with an acute coronary syndrome and was initiated on atorvastatin. However, patient developed atorvastatin induced rhabdomyolysis, with non oliguric renal failure, which subsequently improved on cessation of medication.

UR - http://www.scopus.com/inward/record.url?scp=85014382929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014382929&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2017/24491.9359

DO - 10.7860/JCDR/2017/24491.9359

M3 - Article

VL - 11

SP - FD01-FD02

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 3

ER -